Fimasartan base Fimasartan base manufacturer/supplier 247257-48-3
We can provide GMP validation service that complies with SFDA, FDA, WHO and EU EMPA.Excellent registration team could help us easlily to register our products in different countries.If you and your customer are interested in some products or need CMO business service because of capacity limit, product cost limit or developing limit, plz feel free to contact us.
Besides, we could discuss the possible FDF distribution business. Hope to get the chance to discuss deeply.
Hangzhou Jinlan Pharm-Drugs Technology Co., Limited is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int’l Airport and Shanghai Pudong Int’l Airport, the transportation and production environment are excellent.
We have established well market channels both domestically and overseas. Now JINLAN PHARMA is authorized by some Chinese chemical factories as universal agency and international area agency. Our products are exported to more than 100 countries and enjoy a well reputation, including Europe, USA, South America, India, south-east Asia and so on. Such as Canada, Germany, Spain, Australia, Russia, UAE, Estonia, Indonesia, Egypt, Pakistan and so on. Our machines with Excellent quality, Competitive price, Good after-service, are highly welcomed by our customers. We are pleased to know you and hope to be good friend and cooperator with you for our products. I am sure you will be satisfied with us.
Based on the philosophy of “Human-orient, Technical first, Quality product and High efficiency, Fact and Innovation”, JINLAN PHARMA highly welcome friends from all over the world to cooperate and get co-development.
Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea in September 9, 2010 and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership.
Chemical Name |
2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide |
Synonyms |
|
CAS No. |
247257-48-3 |
Molecular Formula |
C27H31N7OS |
Molecular Weight |
501.64600 |
PSA |
124.68000 |
LogP |
4.22120 |
UNII |
P58222188P |
Density |
1.25g/cm3 |
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View